Respiratory Syncytial Virus: Pathology, therapeutic drugs and prophylaxis

Immunology Letters

Volumn 162, Issue 1, 2014, Pages 237-247

  Gomez, Roberto S ^a,c   Guisle Marsollier, Isabelle ^c   Bohmwald, Karen ^a   Bueno, Susan M ^a,c   Kalergis, Alexis M ^a,b,c  

^a Pontificia Universidad Católica de Chile   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c INSERM   (France)

Author keywords

Human Respiratory Syncytial Virus; Immunity; Infection; Prophylaxis; Therapeutics; Vaccine

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; BCG VACCINE; CPTS 248/404 VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GLYCOPROTEIN F VACCINE; MEDI 559; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; THROMBOSPONDIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ADENOVIRUS; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MACROPHAGE; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VIRAL CLEARANCE; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS GENOME; VIRUS LOAD; VIRUS PARTICLE; VIRUS TRANSMISSION; ANIMAL; ANTAGONISTS AND INHIBITORS; HOST PATHOGEN INTERACTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; PHYSIOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANIMALS; ANTIVIRAL AGENTS; HOST-PATHOGEN INTERACTIONS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL PROTEINS;

EID: 84908316050     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.09.006     Document Type: Review

References (170)

1. Domachowske J.B., Rosenberg H.F. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 1999, 12:298-309.
2. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008, 82:2040-2055.
3. Mejias A., Chavez-Bueno S., Jafri H.S., Ramilo O. Respiratory syncytial virus infections: old challenges and new opportunities. Pediatr Infect Dis J 2005, 24:S189-S196. discussion S196-7.
4. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
5. van Drunen Littel-van den Hurk S., Watkiss E.R. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012, 2:300-305.
6. Navas L., Wang E., de Carvalho V., Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992, 121:348-354.
7. Wang E.E., Law B.J., Boucher F.D., Stephens D., Robinson J.L., Dobson S., et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1996, 129:390-395.
8. Martinez F.D. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003, 22:S76-S82.
9. Sweetman L.L., Ng Y.T., Butler I.J., Bodensteiner J.B. Neurologic complications associated with respiratory syncytial virus. Pediatr Neurol 2005, 32:307-310.
10. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection - a systematic review. Crit Care 2006, 10:R107.
11. Eisenhut M. Cerebral involvement in respiratory syncytial virus disease. Brain Dev 2007, 29:454.
12. Morichi S., Kawashima H., Ioi H., Yamanaka G., Kashiwagi Y., Hoshika A., et al. Classification of acute encephalopathy in respiratory syncytial virus infection. J Infect Chemother 2011, 17:776-781.
13. Espinoza J.A., Bohmwald K., Cespedes P.F., Gomez R.S., Riquelme S.A., Cortes C.M., et al. Impaired learning resulting from respiratory syncytial virus infection. Proc Natl Acad Sci U S A 2013, 110:9112-9117.
14. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998, 102:1211-1216. Newborn AAoPCoIDaCoFa.
15. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.
16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. Group TI-RS.
17. Mejias A., Chavez-Bueno S., Rios A.M., Saavedra-Lozano J., Fonseca Aten M., Hatfield J., et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004, 48:1811-1822.
18. Harkensee C., Brodlie M., Embleton N.D., McKean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect 2006, 52:2-8.
19. Embleton N.D., Harkensee C., McKean M.C. Palivizumab for preterm infants. Is it worth it?. Arch Dis Child Fetal Neonatal Ed 2005, 90:F286-F289.
20. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
21. Welliver R.C., Kaul T.N., Sun M., Ogra P.L. Defective regulation of immune responses in respiratory syncytial virus infection. J Immunol 1984, 133:1925-1930.
22. Welliver R.C., Wong D.T., Sun M., Middleton E., Vaughan R.S., Ogra P.L. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med 1981, 305:841-846.
23. Prince G.A., Prieels J.P., Slaoui M., Porter D.D. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest 1999, 79:1385-1392.
24. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001, 82:2881-2888.
25. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196:859-865.
26. Bueno S.M., Gonzalez P.A., Pacheco R., Leiva E.D., Cautivo K.M., Tobar H.E., et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008, 8:1320-1329.
27. Blount R.E., Morris J.A., Savage R.E. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956, 92:544-549.
28. Chanock R., Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 1957, 66:291-300.
29. Chanock R., Roizman B., Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957, 66:281-290.
30. Chang A., Dutch R.E. Paramyxovirus fusion and entry: multiple paths to a common end. Viruses 2012, 4:613-636.
31. Gould P.S., Easton A.J. Coupled translation of the second open reading frame of M2 mRNA is sequence dependent and differs significantly within the subfamily Pneumovirinae. J Virol 2007, 81:8488-8496.
32. Hacking D., Hull J. Respiratory syncytial virus - viral biology and the host response. J Infect 2002, 45:18-24.
33. Cowton V.M., McGivern D.R., Fearns R. Unravelling the complexities of respiratory syncytial virus RNA synthesis. J Gen Virol 2006, 87:1805-1821.
34. Ogra P.L. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004, 5(Suppl. A):S119-S126.
35. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162:80-99.
36. Gan S.W., Ng L., Lin X., Gong X., Torres J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci 2008, 17:813-820.
37. Batonick M., Wertz G.W. Requirements for human respiratory syncytial virus glycoproteins in assembly and egress from infected cells. Adv Virol 2011, 2011.
38. Liljeroos L., Krzyzaniak M.A., Helenius A., Butcher S.J. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 2013, 110:11133-11138.
39. Pretel E., Camporeale G., de Prat-Gay G. The non-structural NS1 protein unique to respiratory syncytial virus: a two-state folding monomer in quasi-equilibrium with a stable spherical oligomer. PLOS ONE 2013, 8:e74338.
40. Teng M.N., Whitehead S.S., Collins P.L. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001, 289:283-296.
41. Hall C.B., Douglas R.G., Schnabel K.C., Geiman J.M. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 1981, 33:779-783.
42. Lotz M.T., Peebles R.S. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr Allergy Asthma Rep 2012, 12:380-387.
43. Mastrangelo P., Hegele R.G. RSV fusion: time for a new model. Viruses 2013, 5:873-885.
44. Tayyari F., Marchant D., Moraes T.J., Duan W., Mastrangelo P., Hegele R.G. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 2011, 17:1132-1135.
45. Lay M.K., Gonzalez P.A., Leon M.A., Cespedes P.F., Bueno S.M., Riedel C.A., et al. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect 2013, 15:230-242.
46. Hall C.B., Simoes E.A., Anderson L.J. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol 2013, 372:39-57.
47. Welliver R.C. The immune response to respiratory syncytial virus infection: friend or foe. Clin Rev Allergy Immunol 2008, 34:163-173.
48. Roymans D., Koul A. Treatment of respiratory syncytial virus infection: past, present and future. Human respiratory syncytial virus infection 2011, 39. In Tech. B. Resch (Ed.).
49. Houben M.L., Coenjaerts F.E., Rossen J.W., Belderbos M.E., Hofland R.W., Kimpen J.L., et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol 2010, 82:1266-1271.
50. Kim H.W., Leikin S.L., Arrobio J., Brandt C.D., Chanock R.M., Parrott R.H. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976, 10:75-78.
51. Scott R., Kaul A., Scott M., Chiba Y., Ogra P.L. Development of in vitro correlates of cell-mediated immunity to respiratory syncytial virus infection in humans. J Infect Dis 1978, 137:810-817.
52. Siezen C.L., Bont L., Hodemaekers H.M., Ermers M.J., Doornbos G., Van't Slot R., et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr Infect Dis J 2009, 28:333-335.
53. Simoes E.A. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003, 143:S118-S126.
54. Gut W., Pancer K., Abramczuk E., Czescik A., Dunal-Szczepaniak M., Lipka B., et al. RSV respiratory infection in children under 5 y.o.-dynamics of the immune response Th1/Th2 and IgE. Przegl Epidemiol 2013, 67:17-22. 105-9.
55. Lee H.C., Headley M.B., Loo Y.M., Berlin A., Gale M., Debley J.S., et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012, 130:1187-1196. e1185.
56. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy - a review. Virus Genes 2006, 33:235-252.
57. Sigurs N., Bjarnason R., Sigurbergsson F., Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000, 161:1501-1507.
58. Krishnamoorthy N., Khare A., Oriss T.B., Raundhal M., Morse C., Yarlagadda M., et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med 2012, 18:1525-1530.
59. Whimbey E., Couch R.B., Englund J.A., Andreeff M., Goodrich J.M., Raad I.I., et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995, 21:376-379.
60. Torres J.P., Gomez A.M., Khokhar S., Bhoj V.G., Tagliabue C., Chang M.L., et al. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respir Res 2010, 11:125.
61. Millichap J.J., Wainwright M.S. Neurological complications of respiratory syncytial virus infection: case series and review of literature. J Child Neurol 2009, 24:1499-1503.
62. Bueno S.M., Gonzalez P.A., Riedel C.A., Carreno L.J., Vasquez A.E., Kalergis A.M. Local cytokine response upon respiratory syncytial virus infection. Immunol Lett 2011, 136:122-129.
63. Bermejo-Martin J.F., Garcia-Arevalo M.C., De Lejarazu R.O., Ardura J., Eiros J.M., Alonso A., et al. Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. Eur Cytokine Netw 2007, 18:162-167.
64. Culley F.J., Pennycook A.M., Tregoning J.S., Dodd J.S., Walzl G., Wells T.N., et al. Role of CCL5 (RANTES) in viral lung disease. J Virol 2006, 80:8151-8157.
65. Garofalo R.P., Patti J., Hintz K.A., Hill V., Ogra P.L., Welliver R.C. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 2001, 184:393-399.
66. Oshansky C.M., Barber J.P., Crabtree J., Tripp R.A. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis 2010, 201:1201-1207.
67. Rosenberg H.F., Domachowske J.B. Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics. Curr Med Chem 2012, 19:1424-1431.
68. Tripp R.A., Oshansky C., Alvarez R. Cytokines and respiratory syncytial virus infection. Proc Am Thorac Soc 2005, 2:147-149.
69. Jaovisidha P., Peeples M.E., Brees A.A., Carpenter L.R., Moy J.N. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J Immunol 1999, 163:2816-2820.
70. de Graaff P.M., de Jong E.C., van Capel T.M., van Dijk M.E., Roholl P.J., Boes J., et al. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4T cells. J Immunol 2005, 175:5904-5911.
71. Panuska J.R., Hertz M.I., Taraf H., Villani A., Cirino N.M. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am Rev Respir Dis 1992, 145:934-939.
72. Bartz H., Buning-Pfaue F., Turkel O., Schauer U. Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells. Clin Exp Immunol 2002, 129:438-445.
73. Guerrero-Plata A., Casola A., Suarez G., Yu X., Spetch L., Peeples M.E., et al. Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. Am J Respir Cell Mol Biol 2006, 34:320-329.
74. Pribul P.K., Harker J., Wang B., Wang H., Tregoning J.S., Schwarze J., et al. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol 2008, 82:4441-4448.
75. Reed J.L., Brewah Y.A., Delaney T., Welliver T., Burwell T., Benjamin E., et al. Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis 2008, 198:1783-1793.
76. Empey K.M., Orend J.G., Peebles R.S., Egana L., Norris K.A., Oury T.D., et al. Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection. PLoS ONE 2012, 7:e40499.
77. Dakhama A., Vitalis T.Z., Hegele R.G. Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guinea-pig model of acute bronchiolitis. Eur Respir J 1997, 10:20-26.
78. Williams J.V., Weitkamp J.H., Blum D.L., LaFleur B.J., Crowe J.E. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. Mol Immunol 2009, 47:407-414.
79. Valosky J., Hishiki H., Zaoutis T.E., Coffin S.E. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Clin Diagn Lab Immunol 2005, 12:171-179.
80. Angel Rico M., Trento A., Ramos M., Johnstone C., Del Val M., Melero J.A., et al. Human respiratory syncytial virus infects and induces activation markers in mouse B lymphocytes. Immunol Cell Biol 2009, 87:344-350.
81. Rico M.A., Infantes S., Ramos M., Trento A., Johnstone C., Melero J.A., et al. TLR4-independent upregulation of activation markers in mouse B lymphocytes infected by HRSV. Mol Immunol 2010, 47:1802-1807.
82. Gonzalez P.A., Prado C.E., Leiva E.D., Carreno L.J., Bueno S.M., Riedel C.A., et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci U S A 2008, 105:14999-15004.
83. + T cells. J Immunol 2009, 182:4865-4873.
84. Dodd J., Riffault S., Kodituwakku J.S., Hayday A.C., Openshaw P.J. Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. J Immunol 2009, 182:1174-1181.
85. + T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 2008, 26:2020-2033.
86. Kolli D., Bataki E.L., Spetch L., Guerrero-Plata A., Jewell A.M., Piedra P.A., et al. T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection. J Virol 2008, 82:8560-8569.
87. Frey S., Krempl C.D., Schmitt-Graff A., Ehl S. Role of T cells in virus control and disease after infection with pneumonia virus of mice. J Virol 2008, 82:11619-11627.
88. Shishkova Y., Harms H., Krohne G., Avota E., Schneider-Schaulies S. Immune synapses formed with measles virus-infected dendritic cells are unstable and fail to sustain T cell activation. Cell Microbiol 2007, 9:1974-1986.
89. + T-cell memory in the respiratory tract. Nat Med 2002, 8:54-60.
90. Chang J., Choi S.Y., Jin H.T., Sung Y.C., Braciale T.J. Improved effector activity and memory CD8T cell development by IL-2 expression during experimental respiratory syncytial virus infection. J Immunol 2004, 172:503-508.
91. Vallbracht S., Unsold H., Ehl S. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. Eur J Immunol 2006, 36:1434-1442.
92. Olson M.R., Varga S.M. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines 2008, 7:1239-1255.
93. Varga S.M., Wang X., Welsh R.M., Braciale T.J. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001, 15:637-646.
94. Cyr S.L., Jones T., Stoica-Popescu I., Brewer A., Chabot S., Lussier M., et al. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine 2007, 25:5378-5389.
95. Zeng R., Zhang Z., Mei X., Gong W., Wei L. Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-like protein in mice. Biochem Biophys Res Commun 2008, 377:495-499.
96. Bukreyev A., Belyakov I.M., Berzofsky J.A., Murphy B.R., Collins P.L. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J Virol 2001, 75:12128-12140.
97. Bukreyev A., Whitehead S.S., Prussin C., Murphy B.R., Collins P.L. Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines. J Virol 2000, 74:7151-7157.
98. Voges B., Vallbracht S., Zimmer G., Bossow S., Neubert W.J., Richter K., et al. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. Cell Immunol 2007, 247:85-94.
99. Bueno S.M., Gonzalez P.A., Cautivo K.M., Mora J.E., Leiva E.D., Tobar H.E., et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A 2008, 105:20822-20827.
100. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163:693-698.
101. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543-546.
102. Murphy B.R., Graham B.S., Prince G.A., Walsh E.E., Chanock R.M., Karzon D.T., et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 1986, 23:1009-1014.
103. Adkins B., Leclerc C., Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004, 4:553-564.
104. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379-390.
105. + T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol 2009, 83:3019-3028.
106. + CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8T cell response during respiratory syncytial virus infection. J Immunol 2010, 185:2382-2392.
107. + natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010, 84:8790-8798.
108. Loebbermann J., Thornton H., Durant L., Sparwasser T., Webster K.E., Sprent J., et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol 2012, 5:161-172.
109. Durant L.R., Makris S., Voorburg C.M., Loebbermann J., Johansson C., Openshaw P.J. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol 2013, 87:10946-10954.
110. Raiden S., Pandolfi J., Payaslian F., Anderson M., Rivarola N., Ferrero F., et al. Depletion of circulating regulatory T cells during severe respiratory syncytial virus infection in young children. Am J Respir Crit Care Med 2014, 189:865-868.
111. Loebbermann J., Durant L., Thornton H., Johansson C., Openshaw P.J. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci U S A 2013, 110:2987-2992.
112. Law B.J., Wang E.E., MacDonald N., McDonald J., Dobson S., Boucher F., et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics 1997, 99:E7.
113. Ventre K., Randolph A.G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007, CD000181.
114. Andries K., Moeremans M., Gevers T., Willebrords R., Sommen C., Lacrampe J., et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 2003, 60:209-219.
115. Douglas J.L., Panis M.L., Ho E., Lin K.Y., Krawczyk S.H., Grant D.M., et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother 2005, 49:2460-2466.
116. Dunn M.C., Knight D.A., Waldman W.J. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir Ther 2011, 16:309-317.
117. Olszewska W., Ispas G., Schnoeller C., Sawant D., Van de Casteele T., Nauwelaers D., et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J 2011, 38:401-408.
118. Razinkov V., Gazumyan A., Nikitenko A., Ellestad G., Krishnamurthy G. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol 2001, 8:645-659.
119. Sun Z., Pan Y., Jiang S., Lu L. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses 2013, 5:211-225.
120. Friedewald W.T., Forsyth B.R., Smith C.B., Gharpure M.A., Chanock R.M. Low-temperature-grown RS virus in adult volunteers. JAMA 1968, 204:690-694.
121. Schickli J.H., Kaur J., Tang R.S. Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures. Virus Res 2012, 169:38-47.
122. Lindell D.M., Morris S.B., White M.P., Kallal L.E., Lundy P.K., Hamouda T., et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE 2011, 6:e21823.
123. Schepens B., Ibanez L.I., De Baets S., Hultberg A., Bogaert P., De Bleser P., et al. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis 2011, 204:1692-1701.
124. Vanlandschoot P., Stortelers C., Beirnaert E., Ibanez L.I., Schepens B., Depla E., et al. Nanobodies(R): new ammunition to battle viruses. Antiviral Res 2011, 92:389-407.
125. Hultberg A., Temperton N.J., Rosseels V., Koenders M., Gonzalez-Pajuelo M., Schepens B., et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS ONE 2011, 6:e17665.
126. Rigter A., Widjaja I., Versantvoort H., Coenjaerts F.E., van Roosmalen M., Leenhouts K., et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS ONE 2013, 8:e71072.
127. Kaufmann J.K., Nettelbeck D.M. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med 2012, 18:365-376.
128. Matthews Q.L., Fatima A., Tang Y., Perry B.A., Tsuruta Y., Komarova S., et al. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS ONE 2010, 5:e11815.
129. Schuldt N.J., Amalfitano A. Malaria vaccines: focus on adenovirus based vectors. Vaccine 2012, 30:5191-5198.
130. Shao H.Y., Yu S.L., Sia C., Chen Y., Chitra E., Chen I.H., et al. Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine 2009, 27:5460-5471.
131. Krause A., Xu Y., Ross S., Wu W., Joh J., Worgall S. Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. Virol J 2011, 8:375.
132. De Baets S., Schepens B., Sedeyn K., Schotsaert M., Roose K., Bogaert P., et al. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice. J Virol 2013, 87:3314-3323.
133. Quan F.S., Kim Y., Lee S., Yi H., Kang S.M., Bozja J., et al. Virus like particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011, 204:987-995.
134. Garg R., Latimer L., Simko E., Gerdts V., Potter A., van den Hurk S. Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. J Gen Virol 2014, 95:301-306.
135. Garlapati S., Garg R., Brownlie R., Latimer L., Simko E., Hancock R.E., et al. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 2012, 30:5206-5214.
136. Garg R., Latimer L., Gerdts V., Potter A., van Drunen Littel-van den Hurk S. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. J Gen Virol 2014, 95:1043-1054.
137. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE 2012, 7:e50852.
138. Glenn G.M., Smith G., Fries L., Raghunandan R., Lu H., Zhou B., et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31:524-532.
139. Cherukuri A., Stokes K.L., Patton K., Kuo H., Sakamoto K., Lambert S., et al. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing 2012, 9:21.
140. Henderson E.A., Alber D.G., Baxter R.C., Bithell S.K., Budworth J., Carter M.C., et al. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem 2007, 50:1685-1692.
141. Chapman J., Abbott E., Alber D.G., Baxter R.C., Bithell S.K., Henderson E.A., et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 2007, 51:3346-3353.
142. Barik S. Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs. Methods Mol Biol 2009, 487:331-341.
143. Zhang W., Tripp R.A. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol 2008, 82:12221-12231.
144. Bitko V., Musiyenko A., Shulyayeva O., Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11:50-55.
145. DeVincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 2010, 107:8800-8805.
146. Fennelly G.J., Flynn J.L., Ter Meulen V., Liebert U.G., Bloom B.R. Recombinant bacille Calmette-Guerin priming against measles. J Infect Dis 1995, 172:698-705.
147. Dennehy M., Bourn W., Steele D., Williamson A.L. Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. Vaccine 2007, 25:3646-3657.
148. Cautivo K.M., Bueno S.M., Cortes C.M., Wozniak A., Riedel C.A., Kalergis A.M. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection. J Immunol 2010, 185:7633-7645.
149. Widjojoatmodjo M.N., Boes J., van Bers M., van Remmerden Y., Roholl P.J., Luytjes W. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J 2010, 7:114.
150. Haynes L.M., Caidi H., Radu G.U., Miao C., Harcourt J.L., Tripp R.A., et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009, 200:439-447.
151. Jorquera P.A., Choi Y., Oakley K.E., Powell T.J., Boyd J.G., Palath N., et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLOS ONE 2013, 8:e74905.
152. Rey G.U., Miao C., Caidi H., Trivedi S.U., Harcourt J.L., Tripp R.A., et al. Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice. PLOS ONE 2013, 8:e83075.
153. + T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J Virol 2012, 86:13016-13024.
154. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182:1331-1342.
155. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005, 191:1093-1104.
156. Luongo C., Winter C.C., Collins P.L., Buchholz U.J. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 2013, 87:1985-1996.
157. Kamphuis T., Shafique M., Meijerhof T., Stegmann T., Wilschut J., de Haan A. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Vaccine 2013, 31:2169-2176.
158. Kamphuis T., Meijerhof T., Stegmann T., Lederhofer J., Wilschut J., de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS ONE 2012, 7:e36812.
159. Stegmann T., Kamphuis T., Meijerhof T., Goud E., de Haan A., Wilschut J. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation. Vaccine 2010, 28:5543-5550.
160. Englund J., Glezen W.P., Piedra P.A. Maternal immunization against viral disease. Vaccine 1998, 16:1456-1463.
161. Chu H.Y., Englund J.A. Maternal immunization. Clin Infect Dis 2014, 59:484-492.
162. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21:3465-3467.
163. Kwon Y.M., Hwang H.S., Lee J.S., Ko E.J., Yoo S.E., Kim M.C., et al. Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res 2014, 104:1-6.
164. Nielsen H.E., Siersma V., Andersen S., Gahrn-Hansen B., Mordhorst C.H., Norgaard-Pedersen B., et al. Respiratory syncytial virus infection - risk factors for hospital admission: a case-control study. Acta Paediatr 2003, 92:1314-1321.
165. Eick A., Karron R., Shaw J., Thumar B., Reid R., Santosham M., et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J 2008, 27:207-212.
166. Parrott R.H., Kim H.W., Arrobio J.O., Hodes D.S., Murphy B.R., Brandt C.D., et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973, 98:289-300.
167. Bulkow L.R., Singleton R.J., Karron R.A., Harrison L.H. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002, 109:210-216.
168. Stensballe L.G., Ravn H., Kristensen K., Agerskov K., Meakins T., Aaby P., et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009, 123:398-403.
169. Shinoff J.J., O'Brien K.L., Thumar B., Shaw J.B., Reid R., Hua W., et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008, 198:1007-1015.
170. Kaaijk P., Luytjes W., Rots N.Y. Vaccination against RSV: is maternal vaccination a good alternative to other approaches. Hum Vaccin Immunother 2013, 9:1263-1267.